Brett Hughes
About
Brett Hughes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology.
According to data from OpenAlex, Brett Hughes has authored 179 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 84 papers in Pulmonary and Respiratory Medicine and 38 papers in Otorhinolaryngology. Recurrent topics in Brett Hughes's work include Cancer Immunotherapy and Biomarkers (50 papers), Lung Cancer Treatments and Mutations (46 papers) and Head and Neck Cancer Studies (38 papers). Brett Hughes is often cited by papers focused on Cancer Immunotherapy and Biomarkers (50 papers), Lung Cancer Treatments and Mutations (46 papers) and Head and Neck Cancer Studies (38 papers). Brett Hughes collaborates with scholars based in Australia, United States and Spain. Brett Hughes's co-authors include Bryan Chan, Liz Kenny, Teresa Brown, Charles Lin, Merrilyn Banks, Rodney J. Hicks, Kenneth J. O’Byrne, Bernard M. Fine, Andrea Pirzkall and Lukas C. Amler and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.
In The Last Decade
Brett Hughes
168 papers receiving 4.3k citations
Hit Papers
Peers
Brett Hughes
Heather Lin United States
Scott A. Laurie Canada
William N. William United States
Derick Lau United States
Joseph S. K. Au China
Glenn Mills United States
Pia Österlund Finland
Sylvie Rottey Belgium
Hans Christiansen Germany
Tawee Tanvetyanon United States
Citations per year, relative to Brett Hughes Brett Hughes (= 1×)
peers
Heather Lin
Countries citing papers authored by Brett Hughes
Since
Specialization
Citations
This map shows the geographic impact of Brett Hughes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett Hughes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett Hughes more than expected).
Fields of papers citing papers by Brett Hughes
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Brett Hughes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett Hughes. The network helps show where Brett Hughes may publish in the future.
Co-authorship network of co-authors of Brett Hughes
This figure shows the co-authorship network connecting the top 25 collaborators of Brett Hughes. A scholar is included among the top collaborators of Brett Hughes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brett Hughes. Brett Hughes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Huang, Xiaomin, Paul Leo, J. Lynn Fink, et al.. (2025). Tumour‐informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post‐treatment. View.
2.
Faltys, Martin, Marliese Alexander, Sagun Parakh, et al.. (2025). Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer. Lung Cancer. 209. 108786–108786.
3.
Ladwa, Rahul, Jenny Lee, Caroline Cooper, et al.. (2025). Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study. Journal of Clinical Oncology. 43(26). 2888–2896.
4.
Dingemans, Anne‐Marie C., Konstantinos Syrigos, Lorenzo Livi, et al.. (2025). Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. Lung Cancer. 207. 108683–108683.
5.
Tahara, Makoto, Richard Greil, Danny Rischin, et al.. (2025). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. European Journal of Cancer. 221. 115395–115395.
6.
Cho, Byoung Chul, Irene Braña, Beatriz Cirauqui, et al.. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer. 23(S1). 1254–1254.
7.
Greil, Richard, Barbara Burtness, Simon Laban, et al.. (2023). 106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study. Immuno-Oncology Technology. 20. 100578–100578.
8.
Brown, Teresa, et al.. (2022). Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy. Head & Neck. 45(2). 417–430.
9.
Ahern, Elizabeth, Natasha Roberts, Bryan Chan, et al.. (2021). Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia. BMJ Open. 11(5). e044655–e044655.
10.
Ahern, Elizabeth, E Ballard, Michele W.L. Teng, et al.. (2019). Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Trials. 20(1). 408–753.
11.
Ward, Elizabeth C., Clare L. Burns, Tracy Comans, et al.. (2019). Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC. Supportive Care in Cancer. 28(4). 1867–1876.
12.
Ahern, Elizabeth, et al.. (2019). Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib. BMJ Case Reports. 12(12). e232868–e232868.
13.
Turner, Jane, Patsy Yates, Liz Kenny, et al.. (2019). The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer. Supportive Care in Cancer. 27(12). 4627–4637.
14.
Ward, Elizabeth C., Clare L. Burns, Anita Pelecanos, et al.. (2018). Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. Supportive Care in Cancer. 27(2). 573–581.
15.
Ward, Elizabeth C., Anita Pelecanos, Clare L. Burns, et al.. (2018). Helical intensity‐modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns. Head & Neck. 40(9). 1955–1966.
16.
Turner, Jane, Patsy Yates, Liz Kenny, et al.. (2014). The ENHANCES study—Enhancing Head and Neck Cancer patients’ Experiences of Survivorship: study protocol for a randomized controlled trial. PubMed Central.
17.
Lin, Charles, Aravind Ravi Kumar, Jacqui Keller, et al.. (2013). 18F-fluoro-L-thymidine Positron Emission Tomography for Mucosal Head and Neck Squamous Cell Carcinoma Treated with Definitive Chemoradiation: A Pilot Study of Nodal Assessment and Tracer Safety. 2013. 1–7.
18.
Punnoose, Elizabeth A., Siminder Atwal, Weiqun Liu, et al.. (2012). Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib. Clinical Cancer Research. 18(8). 2391–2401.
19.
Mileshkin, Linda, Rodney J. Hicks, Brett Hughes, et al.. (2011). Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib. Clinical Cancer Research. 17(10). 3304–3315.
20.
Bowman, Rayleen, Vandana Relan, & Brett Hughes. (2011). Medical management of mesothelioma. Australian Prescriber. 34(5). 144–147.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Heather Lin Breakdown of academic impact, for papers by Scott A. Laurie Breakdown of academic impact, for papers by William N. William Breakdown of academic impact, for papers by Derick Lau Breakdown of academic impact, for papers by Joseph S. K. Au Breakdown of academic impact, for papers by Glenn Mills Breakdown of academic impact, for papers by Pia Österlund Breakdown of academic impact, for papers by Sylvie Rottey Breakdown of academic impact, for papers by Hans Christiansen Breakdown of academic impact, for papers by Tawee Tanvetyanon